MorphoSys to Use BMBF Grant to Look at Protein Biomarkers for Multiple Myeloma Drug Efficacy

The company will use part of the €1 million award to investigate biomarkers that will aid in determining which patients are the best candidates for treatment with its MOR202 antibody program, a company official said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.